Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a progressive form of liver disease closely linked to metabolic disorders. It is previously known as Non-Alcoholic Steatohepatitis (NASH). It is associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. The main pathological features of MASH include fat accumulating in the liver, inflammation, and damage to liver cells. This condition can advance to more severe liver damage, such as fibrosis, cirrhosis, and even hepatocellular carcinoma. The pathogenesis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) is complex and involves multiple factors, including insulin resistance, oxidative stress, and imbalances in lipid metabolism. Diagnosis often requires imaging, blood tests, and sometimes liver biopsy. Managing Metabolic Dysfunction-Associated Steatohepatitis (MASH) focuses on lifestyle modifications like diet and exercise and addressing underlying metabolic conditions. The growing prevalence of Metabolic Dysfunction-Associated Steatohepatitis (MASH)is a significant public health concern.